U.S. markets close in 3 hours 20 minutes

  • S&P 500

    4,238.27
    +13.48 (+0.32%)
     

  • Dow 30

    33,887.98
    +11.01 (+0.03%)
     

  • Nasdaq

    14,206.67
    +65.19 (+0.46%)
     

  • Russell 2000

    2,280.80
    -5.29 (-0.23%)
     

  • Crude Oil

    73.28
    -0.38 (-0.52%)
     

  • Gold

    1,779.90
    -3.00 (-0.17%)
     

  • Silver

    25.85
    -0.17 (-0.65%)
     

  • EUR/USD

    1.1942
    +0.0017 (+0.14%)
     

  • 10-Yr Bond

    1.4780
    -0.0060 (-0.40%)
     

  • GBP/USD

    1.3939
    +0.0006 (+0.04%)
     

  • USD/JPY

    110.6980
    +0.4000 (+0.36%)
     

  • BTC-USD

    31,976.23
    -335.10 (-1.04%)
     

  • CMC Crypto 200

    762.72
    -31.61 (-3.98%)
     

  • FTSE 100

    7,090.01
    +27.72 (+0.39%)
     

  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

Global Infectious Disease Diagnostics Market Report 2021-2026: Reagents, Kits, and Consumables Segment to Command the Largest Share of the Market / Diagnostic Laboratories Dominate the End-User Market

·4 min read

DUBLIN, June 22, 2021 /PRNewswire/ -- The "Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2% during the forecast period.

Market growth is driven by factors such as global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.

The reagents, kits, and consumables accounted for the highest growth rate in the infectious disease diagnostics market, by product & service, during the forecast period

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the highest growth rate in the infectious disease diagnostics market in 2020. The requirement of reagents, kits and consumables in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of reagents, kits, and consumables compared to instruments.

HAIs segment accounted for the highest CAGR

Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases. The increasing number of cases and the availability of many COVID-19 diagnostic tests are driving the growth of this market. In 2020, the HAIs segment accounted for the highest CAGR.

Diagnostic Laboratories segment accounted for the highest CAGR

Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the highest CAGR. This can be attributed to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

Asia Pacific: The fastest-growing region infections disease diagnostics market

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the infectious disease diagnostics market in this region.

Premium Insights

  • The Rising Adoption of Poc Diagnostics is Expected to Support Market Growth During the Forecast Period

  • Reagents, Kits, and Consumables Segment to Command the Largest Share of the Market, by Product & Service, in 2021

  • Immunodiagnostics to Hold the Largest Share of the Market During the Forecast Period

  • Diagnostic Laboratories Dominate the End-User Market

Market Dynamics

Drivers

  • Global Prevalence of Infectious Diseases and Onset of COVID-19

  • Rising Focus on R&D and Funding in Infectious Disease Diagnostics

  • Growing Awareness for Early Disease Diagnosis in Developing Countries

  • Rising Technological Advancements in Infectious Disease Diagnostics

  • Shift in Focus from Centralized Laboratories to Decentralized Poc Testing

Restraints

  • Unfavorable Reimbursement Scenario

Opportunities

  • Growth Opportunities in Growing Economies

Challenges

  • Changing Regulatory Landscape

  • Operational Barriers

  • COVID-19 Impact Analysis

Pricing Analysis

  • Pricing Analysis of Infectious Disease Diagnostic Products (2021)

Patent Analysis

  • Polymerase Chain Reaction

  • Immunodiagnostics

Value Chain Analysis

Supply Chain Analysis

Ecosystem Analysis

Porter's Five Forces Analysis

PESTLE Analysis

Regulatory Landscape

Trade Analysis

  • Trade Analysis for Culture Media

Technology Analysis

Yc-Ycc Shift

List of Companies Profiled in the Report:

  • Abbott Laboratories (US)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • bioMerieux SA (France)

  • Thermo Fisher Scientific Inc. (US)

  • Danaher Corporation (US)

  • QuidelCorporation(US)

  • Hologic, Inc. (US)

  • PerkinElmer Inc. (US)

  • Bio-Rad Laboratories, Inc. (US)

  • QIAGEN (Netherlands)

  • Siemens Healthineers AG (Germany)

  • Becton, Dickinson and Company (US)

  • DiaSorin S.p.A (Italy)

  • Grifols S.A. (Spain)

  • Sysmex Corporation (Japan)

  • Ortho Clinical Diagnostics (US)

  • Genetic Signatures (Australia)

  • Luminex Corporation (US)

  • Meridian Bioscience (US)

  • OraSure Technologies (US)

  • Trinity Biotech Plc. (Ireland)

  • Chembio Diagnostic Systems, Inc. (US)

  • Seegene Inc. (South Korea)

  • Co-Diagnostics, Inc. (US)

  • ELITechGroup (France)

  • Epitope Diagnostics, Inc. (US)

  • Trivitron Healthcare (India)

  • Meril Life Sciences Pvt. Ltd. (India)

  • InBios International, Inc. (US)

  • ABACUS Diagnostica Oy (Finland)

For more information about this report visit https://www.researchandmarkets.com/r/3cczwj

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/global-infectious-disease-diagnostics-market-report-2021-2026-reagents-kits-and-consumables-segment-to-command-the-largest-share-of-the-market--diagnostic-laboratories-dominate-the-end-user-market-301317367.html

SOURCE Research and Markets

Recommended Stories

  • Gevo Could Be Purchased After Its Successful Test of the Long-Term Average

    During Monday's fast paced "Lightning Round" segment of Mad Money, a caller asked Jim Cramer about a renewable chemicals and biofuel company, Gevo Inc. : "People need to make room in their portfolio for this stock," he replied. The trading volume is hard to read because of the scaling, but the On-Balance-Volume (OBV) line shows a rise into late January followed by a slow and shallow decline. The weekly OBV line has moved steadily higher and only dipped slightly when prices corrected lower.

  • What in the heck is the FDA thinking?

    By John Vandermosten, CFA TSX:PMN.TO | OTC:ARFXF | NASDAQ:BIIB One of the wildest roller coaster rides in biotech has been the aducanumab saga that has been taking place over the last few years. Aducanumab, branded as Aduhelm, is an amyloid beta-directed monoclonal antibody intended for use in the treatment of Alzheimer’s Disease (AD). Aduhelm binds to aggregated forms of amyloid beta and has

  • MNOV: Positive Results for MN-166 in Phase 2 AUD Trial…

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Positive Results for MN-166 in Phase 2 AUD Trial On June 21, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Translational Psychiatry , a Nature publication ( Grodin et al., 2021 ). The trial was a

  • Years of Smoking Weed May Leave You Grasping for Words

    When researchers looked at the marijuana habits of a group of people ages 18 to 30, and then again 25 years later, one finding rose above the fog.

  • Labor shortage impacting airlines’ summer travel

    Mike Boyd, Boyd Group International President, joins Yahoo Finance to discuss the labor shortage impact on airlines amid pandemic recovery and outlook on summer travel.

  • Chinese Bitcoin Mining Company Delivers First Machines to Kazakhstan

    BIT Mining expects to deliver another two batches of machines by the start of July.

  • Covid-19 Showed mRNA Vaccines Work. Translate Bio, Sanofi, Are Testing One for Flu.

    The world has settled for flu vaccines that are no more than 50% effective, so a better product could reshape the market, and perhaps expand it.

  • Amazon and Apple are the most valuable brands in the world — but these Chinese companies are catching up

    These are the top 100 most valuable global brands for 2021, according to a company that analyzes brand equity

  • Iran seizes 7,000 cryptocurrency computer miners, largest haul to date

    Iranian police have seized 7,000 computer miners at an illegal cryptocurrency farm, their largest haul to date of the energy-guzzling machines that have exacerbated power outages in Iran, state media reported on Tuesday. In late May, Iran banned the mining of cryptocurrencies such as Bitcoin for nearly four months as part of efforts to reduce the incidence of power blackouts blamed by officials on surging electricity demand during the searingly hot and dry summer. Tehran police chief General Hossein Rahimi said the 7,000 computer miners were seized in an abandoned factory in the west of the capital, the state news agency IRNA reported.

  • China has once again tanked the entire cryptocurrency market

    When Elon Musk isn’t busy manipulating the cryptocurrency market, China is happy to do so in his place. In a repeat of what we witnessed earlier this year, bitcoin is crashing on Monday, following more bad news from China, where many mining operations have been taken offline. China’s desire to regulate digital currency isn’t new, …

  • Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study

    Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data will be presented at the EASL International Liver Congress 2021. Results in children with familial intrahepatic cholestasis (PFIC) from two Phase 3 studies showed that Bylvay was associated with rapid reductions in serum bile acid levels and improved pruritus severity, with durable clinical benefits sust

  • Rates Are Still Low. Here Are 8 Large-Cap Stocks That Offer Income.

    High-yielding stocks are back in vogue this year as investors hunt for dividends in a low-rate environment and favor value-oriented strategies. Barron’s screened the S&P 500 based on data from S&P Dow Jones Indices for top-yielding stocks and came up with eight companies with dividends in the range of 5% to 7%. Wolfe Research strategist recently noted that high-yielding stocks were historically inexpensive versus the S&P 500 based on price earnings ratios.

  • Bitcoin drops below $30,000 as relentless China crackdown weighs

    Bitcoin on Tuesday fell below $30,000 for the first time since January, briefly erasing gains for the year and adding to losses sparked a day earlier when China's central bank deepened a crackdown on cryptocurrencies. The world's largest cryptocurrency dropped to $28,600, its lowest since early January, after giving up gains made during Asian hours. Bitcoin tumbled 11% on Monday, its largest one-day drop in over a month, with losses of nearly 30% in the last week alone almost wiping out gains for the year-to-date.

  • Chinese Logistics Firm Airlifting Bitcoin Mining Machines to Maryland: Report

    "Compared to the amount of miners that get shipped regularly, it's just a small batch," a mining source told CoinDesk.

  • Israel faces Covid surge as virus circulates even among vaccinated

    Israel has recommended vaccinating teenagers following several coronavirus outbreaks clustered around schools, with even fully vaccinated people contracting the virus as authorities blame the more infectious delta variant. The country reported 125 new cases in 24 hours on Tuesday, the highest one-day total since the end of April. The latest outbreaks were identified in several schools following random testing and came after Israel removed nearly all of its coronavirus restrictions following a dr

  • Key Deutsche Bank Holder Says Time Ripe for Mergers: Qatar Forum

    (Bloomberg) -- One of Deutsche Bank AG’s top shareholders signaled his backing for consolidation in Europe’s financial services industry, arguing at the Qatar Economic Forum on Tuesday that the continent’s lenders need scale to compete globally.Business travel may change in the aftermath of the pandemic, but airline chiefs said they’re confident the so-called road warriors will return to their cabins despite the effectiveness of Covid-era workarounds like Zoom. Earlier, billionaire investor Mich

  • Key Oil Spread Jumps to Seven-Year High in Sign of Supply Crunch

    (Bloomberg) -- A key spread between monthly oil futures contracts has blown out to the widest level in seven years as traders bet that U.S. crude inventories are about to get a whole lot tighter.The premium traders are placing on West Texas Intermediate crude for September delivery over October contracts touched $1.12 a barrel on Monday. Before this, the gap between the third- and fourth-closest contracts had only traded above $1 over two periods in the past 13 years -- in 2008 and from mid-2013

  • Big data’s $12 billion opportunity in the EV space

    Wells Fargo Automotive & Mobility Analyst Colin Langan joins Yahoo Finance to discuss the future of the electric vehicle market as increased investment in EV innovation is driving up competition in the automotive industry.

  • Reality check for Volkswagen in China after sluggish start for electric car series

    Volkswagen AG's ID series - the backbone of its electric vehicle ambitions - is off to what even company sources call a worryingly slow start in China. Sales in May of two ID.4 electric SUV models, launched only two months earlier, came to a mere 1,213 combined. Volkswagen's venture with state-owned SAIC Motor, which makes the slightly bigger ID.4 X model, had been targeting sales of 50,000-60,000 vehicles this year, according to comments by Yang Siyao, a company marketing executive, in Chinese media in March.

  • Halozyme Collaborates with ViiV Healthcare to Develop Ultra-Long-Acting HIV Meds

    Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting medicines for the treatment of HIV. ViiV Healthcare is a pharmaceutical company created as a joint venture by Pfizer and GlaxoSmithKline. It specializes in the development of therapies for HIV infection. The agreement provides ViiV exclusive access to Halozyme’s ENHANZE drug delivery technology. In consideratio